La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Somatic mutations in GRM1 in cancer alter metabotropic glutamate receptor 1 intracellular localization and signaling.

Identifieur interne : 001352 ( Ncbi/Curation ); précédent : 001351; suivant : 001353

Somatic mutations in GRM1 in cancer alter metabotropic glutamate receptor 1 intracellular localization and signaling.

Auteurs : Jessica L. Esseltine [Canada] ; Melinda D. Willard ; Isabella H. Wulur ; Mary E. Lajiness ; Thomas D. Barber ; Stephen S G. Ferguson

Source :

RBID : pubmed:23303475

English descriptors

Abstract

The activity of metabotropic glutamate receptors (mGluRs) is known to be altered as the consequence of neurodegenerative diseases such as Alzheimer, Parkinson, and Huntington disease. However, little attention has been paid to this receptor family's potential link with cancer. Recent reports indicate altered mGluR signaling in various tumor types, and several somatic mutations in mGluR1a in lung cancer were recently described. Group 1 mGluRs (mGluR1a and mGluR5) are coupled primarily to Gαq, leading to the activation of phospholipase C and to the formation of diacylglycerol and inositol 1,4,5-trisphosphate, leading to the release of Ca(2+) from intracellular stores and protein kinase C (PKC) activation. In the present study, we investigated the intracellular localization and G protein-dependent and -independent signaling of eight GRM1 (mGluR1a) somatic mutations. Two mutants found in close proximity to the glutamate binding domain and cysteine-rich region (R375G and G396V) show both decreased cell surface expression and basal inositol phosphate (IP) formation. However, R375G shows increased ERK1/2 activation in response to quisqualate stimulation. A mutant located directly in the glutamate binding site (A168V) shows increased quisqualate-induced IP formation and, similar to R375G, increased ERK1/2 activation. Additionally, a mutation in the G protein-coupled receptor kinase 2/PKC regulatory region (R696W) shows decreased ERK1/2 activation, whereas a mutation within the Homer binding region in the carboxyl-terminal tail (P1148L) does not alter the intracellular localization of the receptor, but it induces changes in cellular morphology and exhibits reduced ERK1/2 activation. Taken together, these results suggest that mGluR1a signaling in cancer is disrupted by somatic mutations with multiple downstream consequences.

DOI: 10.1124/mol.112.081695
PubMed: 23303475

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:23303475

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Somatic mutations in GRM1 in cancer alter metabotropic glutamate receptor 1 intracellular localization and signaling.</title>
<author>
<name sortKey="Esseltine, Jessica L" sort="Esseltine, Jessica L" uniqKey="Esseltine J" first="Jessica L" last="Esseltine">Jessica L. Esseltine</name>
<affiliation wicri:level="1">
<nlm:affiliation>Molecular Brain Research Group, Robarts Research Institute and Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Molecular Brain Research Group, Robarts Research Institute and Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Willard, Melinda D" sort="Willard, Melinda D" uniqKey="Willard M" first="Melinda D" last="Willard">Melinda D. Willard</name>
</author>
<author>
<name sortKey="Wulur, Isabella H" sort="Wulur, Isabella H" uniqKey="Wulur I" first="Isabella H" last="Wulur">Isabella H. Wulur</name>
</author>
<author>
<name sortKey="Lajiness, Mary E" sort="Lajiness, Mary E" uniqKey="Lajiness M" first="Mary E" last="Lajiness">Mary E. Lajiness</name>
</author>
<author>
<name sortKey="Barber, Thomas D" sort="Barber, Thomas D" uniqKey="Barber T" first="Thomas D" last="Barber">Thomas D. Barber</name>
</author>
<author>
<name sortKey="Ferguson, Stephen S G" sort="Ferguson, Stephen S G" uniqKey="Ferguson S" first="Stephen S G" last="Ferguson">Stephen S G. Ferguson</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23303475</idno>
<idno type="pmid">23303475</idno>
<idno type="doi">10.1124/mol.112.081695</idno>
<idno type="wicri:Area/PubMed/Corpus">000942</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000942</idno>
<idno type="wicri:Area/PubMed/Curation">000942</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000942</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000942</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000942</idno>
<idno type="wicri:Area/Ncbi/Merge">001352</idno>
<idno type="wicri:Area/Ncbi/Curation">001352</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Somatic mutations in GRM1 in cancer alter metabotropic glutamate receptor 1 intracellular localization and signaling.</title>
<author>
<name sortKey="Esseltine, Jessica L" sort="Esseltine, Jessica L" uniqKey="Esseltine J" first="Jessica L" last="Esseltine">Jessica L. Esseltine</name>
<affiliation wicri:level="1">
<nlm:affiliation>Molecular Brain Research Group, Robarts Research Institute and Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Molecular Brain Research Group, Robarts Research Institute and Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Willard, Melinda D" sort="Willard, Melinda D" uniqKey="Willard M" first="Melinda D" last="Willard">Melinda D. Willard</name>
</author>
<author>
<name sortKey="Wulur, Isabella H" sort="Wulur, Isabella H" uniqKey="Wulur I" first="Isabella H" last="Wulur">Isabella H. Wulur</name>
</author>
<author>
<name sortKey="Lajiness, Mary E" sort="Lajiness, Mary E" uniqKey="Lajiness M" first="Mary E" last="Lajiness">Mary E. Lajiness</name>
</author>
<author>
<name sortKey="Barber, Thomas D" sort="Barber, Thomas D" uniqKey="Barber T" first="Thomas D" last="Barber">Thomas D. Barber</name>
</author>
<author>
<name sortKey="Ferguson, Stephen S G" sort="Ferguson, Stephen S G" uniqKey="Ferguson S" first="Stephen S G" last="Ferguson">Stephen S G. Ferguson</name>
</author>
</analytic>
<series>
<title level="j">Molecular pharmacology</title>
<idno type="eISSN">1521-0111</idno>
<imprint>
<date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Down-Regulation (genetics)</term>
<term>Equidae</term>
<term>Genetic Variation (genetics)</term>
<term>HEK293 Cells</term>
<term>Humans</term>
<term>Intracellular Fluid (metabolism)</term>
<term>Intracellular Fluid (physiology)</term>
<term>Intracellular Membranes (chemistry)</term>
<term>Intracellular Membranes (metabolism)</term>
<term>Intracellular Membranes (pathology)</term>
<term>Mutation (genetics)</term>
<term>Neoplasms (genetics)</term>
<term>Neoplasms (metabolism)</term>
<term>Neoplasms (pathology)</term>
<term>Receptors, Metabotropic Glutamate (chemistry)</term>
<term>Receptors, Metabotropic Glutamate (genetics)</term>
<term>Receptors, Metabotropic Glutamate (metabolism)</term>
<term>Signal Transduction (genetics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en">
<term>Receptors, Metabotropic Glutamate</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en">
<term>Intracellular Membranes</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Down-Regulation</term>
<term>Genetic Variation</term>
<term>Mutation</term>
<term>Neoplasms</term>
<term>Receptors, Metabotropic Glutamate</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Intracellular Fluid</term>
<term>Intracellular Membranes</term>
<term>Neoplasms</term>
<term>Receptors, Metabotropic Glutamate</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Intracellular Membranes</term>
<term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Intracellular Fluid</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Equidae</term>
<term>HEK293 Cells</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The activity of metabotropic glutamate receptors (mGluRs) is known to be altered as the consequence of neurodegenerative diseases such as Alzheimer, Parkinson, and Huntington disease. However, little attention has been paid to this receptor family's potential link with cancer. Recent reports indicate altered mGluR signaling in various tumor types, and several somatic mutations in mGluR1a in lung cancer were recently described. Group 1 mGluRs (mGluR1a and mGluR5) are coupled primarily to Gαq, leading to the activation of phospholipase C and to the formation of diacylglycerol and inositol 1,4,5-trisphosphate, leading to the release of Ca(2+) from intracellular stores and protein kinase C (PKC) activation. In the present study, we investigated the intracellular localization and G protein-dependent and -independent signaling of eight GRM1 (mGluR1a) somatic mutations. Two mutants found in close proximity to the glutamate binding domain and cysteine-rich region (R375G and G396V) show both decreased cell surface expression and basal inositol phosphate (IP) formation. However, R375G shows increased ERK1/2 activation in response to quisqualate stimulation. A mutant located directly in the glutamate binding site (A168V) shows increased quisqualate-induced IP formation and, similar to R375G, increased ERK1/2 activation. Additionally, a mutation in the G protein-coupled receptor kinase 2/PKC regulatory region (R696W) shows decreased ERK1/2 activation, whereas a mutation within the Homer binding region in the carboxyl-terminal tail (P1148L) does not alter the intracellular localization of the receptor, but it induces changes in cellular morphology and exhibits reduced ERK1/2 activation. Taken together, these results suggest that mGluR1a signaling in cancer is disrupted by somatic mutations with multiple downstream consequences.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001352 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001352 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:23303475
   |texte=   Somatic mutations in GRM1 in cancer alter metabotropic glutamate receptor 1 intracellular localization and signaling.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:23303475" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022